Cost-effectiveness analysis of three kinds of schemes in the treatment of acute exacerbation of chronic bronchitis / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
;
(12): 878-879, 2014.
Artículo
en Chino
| WPRIM
| ID: wpr-447880
ABSTRACT
Objective From the point of view of pharmaceutical economics,to analyze and compare the clinical efficacy,safety,compliance and economic effect of three kinds of scheme1.moxifloxacin,2.moxifioxacin combined with ambroxol,3.azithromycin combined with levofloxacin in the treatment of acute exacerbation of chronic bronchitis (AECB).Methods Retrieval Chinese joumal full-text database,Wanfang medical database and Chinese science and technology periodical full-text database,included three options for the treatment of AECB randomized controlled trial (RCT) literature,through the analysis of the data to make drug economics evaluation.Results The total effective rates of three programs were 94.92%,95.08%,94.90%,the difference was not statistically significant (P > 0.05).The cost-effectiveness ratios were 213.34,536.40,61.22.Conclusion The efficacy of three treatment options is similar,azithromycin combined with levofloxacin has economic advantages.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Ensayo Clínico Controlado
/
Evaluación Económica en Salud
Idioma:
Chino
Revista:
Chinese Journal of Primary Medicine and Pharmacy
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS